US FDA’s Drug Shortage Program On ‘Site Engagement’ To Be Nixed In GDUFA III
Executive Summary
Generics industry and FDA also debated inspection policies in lieu of travel and safety restrictions mandated by the pandemic.
You may also be interested in...
GDUFA III Talks Completed
Post-warning letter meetings for manufacturing issues and updates to the complex product meeting process are included in the user fee extension agreement.
GDUFA III Talks Completed; Fees will Fund Inspection, Complex Generic Improvements
Post-warning letter meetings for manufacturing issues and updates to the complex product meeting process are included in the user fee extension agreement.
US GDUFA III Talks In Final Stages, Agreement Nearly Complete
Final commitment letter preparations now under way as revenue issues are resolved.